Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Aileron Therapeutics Inc ALRN

Healthcare Biotechnology
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALRN)

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 8 days ago

Aileron Therapeutics Announces CEO Transition

GlobeNewswire March 12, 2024

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

GlobeNewswire February 15, 2024

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

GlobeNewswire February 1, 2024

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

PR Newswire October 31, 2023

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

GlobeNewswire February 21, 2023

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire November 30, 2022

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

GlobeNewswire November 10, 2022

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

GlobeNewswire November 1, 2022
View More News ››

Opinion & Analysis (NDAQ:ALRN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALRN)

Follow the money!!!

https://www.insidertracking.com/node/7?menu_tickersearch=ALRN+%7C%7C+Aileron+Therapeutics
sblwaterloo2 - August 14, 2020
View more Bullboard ››

Viva Gold Corp.

Viva Gold Corp.

Viva Gold Corp. is a Canada-based gold exploration and development company, The Company’s business is the acquisition ...
View More »